


# **RAW SEQUENCE LISTING** **ERROR REPORT**

BIOTECHNOLOGY  
SYSTEMS  
BRANCH



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: 09/191,997

Art Unit / Team No. : QPK

Date Processed by STIC: 11/23/98

**THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.**

**PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:**

**1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,**

**2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY**

**THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.**

**IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:**

**ARTI SHAH 703-308-4212**

# Raw Sequence Listing Error Summary

## ERROR DETECTED   SUGGESTED   CORRECTION

SERIAL NUMBER:

09/19/997

**ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE**

- 1      **Wrapped Nucleic**      The number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2      **Wrapped Amino**      The amino acid number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3      **Incorrect Line Length**      The rules require that a line not exceed 72 characters in length. This includes spaces.  
All text must be visible on page.
- 4      **Misaligned Amino Acid**      The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs  
**Numbering**      between the numbering. It is recommended to delete any tabs and uses spacing between the numbers.
- 5      **Non-ASCII**      This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.  
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6      **Variable Length**      Sequence(s)      contain n's or Xaa's which represented more than one residue.  
As per the rules, each n or Xaa can only represent a single residue.  
Please present the maximum number of each residue having variable length and  
indicate in the (ix) features section that some may be missing.
- 7      **Wrong Designation**      Sequence(s)      contain amino acid or nucleic acid designators which are not standard  
representations as per the Sequence Rules (Please refer to paragraph 1.822)
- 8      **Skipped Sequences**      Sequence(s)      missing. If intentional, please use the following format for each skipped sequence:  
**(OLD RULES)**      (2) INFORMATION FOR SEQ ID NO:X:  
                         (1) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")  
                         (x1) SEQUENCE DESCRIPTION:SEQ ID NO:X:  
                         This sequence is intentionally skipped  
  
Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9      **Skipped Sequences**      Sequence(s)      missing. If intentional, please use the following format for each skipped sequence.  
**(NEW RULES)**      <210> sequence id number  
                         <400> sequence id number  
                         000
- 10      **Use of N's or Xaa's**      Use of N's and/or Xaa's have been detected in the Sequence Listing.  
**(NEW RULES)**      Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
- 11      **Use of <213>Organism**      Sequence(s)      are missing this mandatory field or its response.  
**(NEW RULES)**
- 12      **Use of <220>Feature**      Sequence(s)      are missing the <220>Feature and associated headings.  
**(NEW RULES)**      Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"  
                         (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32)  
                         (Sec. 1.823 of new Sequence Rules)
- 13      **Wrong Format**      File submitted was in the alphabetical heading format of the Old Sequence Rules. This is invalid since the  
                         "Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures"  
                         Federal Register Notice, Vol. 63, No. 104, June 1, 1998, p. 29620  
                         applies to applications filed on or after July 1, 1998.  
                         AKS-Biotechnology Systems Branch- 7/10/98

PAGE: 1

RAW SEQUENCE LISTING  
PATENT APPLICATION US/09/191,997

DATE: 11/23/1998  
TIME: 16:18:32

Input Set: I191997.RAW

This Raw Listing contains the General  
Information Section and those Sequences  
containing ERRORS.

1 <110> Edwards, Jean-Baptiste Dumas Milne  
2 Duclert, Aymeric  
3 Bougueleret, Lydie  
4 <120> Extended cDNAs for Secreted Proteins  
5 <130> GENSET.016A  
6 <150> 60/066,677  
7 <151> 1997-11-13  
8 <160> 227  
9 <170> Patent.pm

*new format*

*>[140] add these  
[147] human identifiers  
and responses, now  
that a serial number  
has been assigned*

*Does Not Comply  
Corrected Diskette Needed*

ERRORED SEQUENCES FOLLOW

E--> 10 <210> 227  
11 <211> 241  
12 <212> PRT  
13 <213> Homo sapiens  
14 <220>  
15 <221> SIGNAL  
16 <222> -103...-1  
17 <400> 227  
18 Met Trp Leu Asp Pro Val Phe Pro Leu Phe Pro Val Gly Asp His Tyr  
19 -100 -95 -90  
20 Leu Pro His Leu His Met Asp Val Leu Glu Gly Leu Ile Leu Val Leu  
21 -85 -80 -75  
22 Pro Cys Ile Asp Val Phe Val Lys Val Asp Leu Arg Thr Val Thr Cys  
23 -70 -65 -60  
24 Asn Ile Pro Pro Gln Glu Ile Leu Thr Arg Asp Ser Val Thr Thr Gln  
25 -55 -50 -45 -40  
26 Val Asp Gly Val Val Tyr Tyr Arg Ile Tyr Ser Ala Val Ser Ala Val  
27 -35 -30 -25  
28 Ala Asn Val Asn Asp Val His Gln Ala Thr Phe Leu Leu Ala Gln Thr  
29 -20 -15 -10  
30 Thr Leu Arg Asn Val Leu Gly Thr Gln Thr Leu Ser Gln Ile Leu Ala  
31 -5 1 5  
32 Gly Arg Glu Glu Ile Ala His Ser Ile Gln Thr Leu Leu Asp Asp Ala  
33 10 15 20 25  
34 Thr Glu Leu Trp Gly Ile Arg Val Ala Arg Val Glu Ile Lys Asp Val  
35 30 35 40  
36 Arg Ile Pro Val Gln Leu Gln Arg Ser Met Ala Ala Glu Ala Glu Ala  
37 45 50 55  
38 Thr Arg Glu Ala Arg Ala Lys Val Leu Ala Ala Glu Gly Glu Met Asn  
39 60 65 70

*next page*

PAGE: 2

RAW SEQUENCE LISTING  
PATENT APPLICATION US/09/191,997DATE: 11/23/1998  
TIME: 16:18:32

Input Set: I191997.RAW

40 Ala Ser Lys Ser Leu Lys Ser Ala Ser Met Val Leu Ala Glu Ser Pro  
41 75 80 85  
42 Ile Ala Leu Gln Leu Arg Tyr Leu Gln Thr Leu Ser Thr Val Ala Thr  
43 90 95 100 105  
44 Glu Lys Asn Ser Thr Ile Val Phe Pro Leu Pro Met Asn Ile Leu Glu  
45 110 115 120  
46 Gly Ile Gly Gly Val Ser Tyr Asp Asn His Lys Lys Leu Pro Asn Lys  
47 125 130 135  
48 Ala

E--> 49  
E--> 50 S:\DOCS\DOH\GENSET\016A.TXT  
E--> 51 111398  
E--> 52 220

*delete**see attached*

PAGE: 3

RAW SEQUENCE LISTING  
PATENT APPLICATION US/09/191,997DATE: 11/27/1998  
TIME: 16:46:46

Input Set: I191997.RAW

95 <210> SEQ ID NO 11  
96 <211> LENGTH: 25  
97 <212> TYPE: DNA  
98 <213> ORGANISM: Artificial Sequence  
99 <220> FEATURE:  
100 <221> NAME/KEY: Oligonucleotide  
101 <400> SEQUENCE: 11  
102 atgggaaagg aaaagactca tatca 25  
103 <210> SEQ ID NO 12  
104 <211> LENGTH: 25  
105 <212> TYPE: DNA  
106 <213> ORGANISM: Artificial Sequence  
107 <220> FEATURE:  
108 <221> NAME/KEY: Oligonucleotide  
109 <400> SEQUENCE: 12  
110 agcagcaaca atcaggacag cacag 25  
111 <210> SEQ ID NO 13  
112 <211> LENGTH: 25  
113 <212> TYPE: DNA  
114 <213> ORGANISM: Artificial Sequence  
115 <220> FEATURE:  
116 <221> NAME/KEY: Oligonucleotide  
117 <400> SEQUENCE: 13  
118 atcaagaatt cgcacgagac catta 25  
119 <210> SEQ ID NO 14  
120 <211> LENGTH: 67  
121 <212> TYPE: DNA  
122 <213> ORGANISM: Artificial Sequence  
123 <220> FEATURE:  
124 <221> NAME/KEY: Oligonucleotide  
125 <400> SEQUENCE: 14  
126 atcgttgaga ctcgtaccag cagagtcacg agagagacta cacagtactg gttttttttt 60  
W--> 127 tttttttt 67  
128 <210> SEQ ID NO 15  
129 <211> LENGTH: 29  
130 <212> TYPE: DNA  
131 <213> ORGANISM: Artificial Sequence  
132 <220> FEATURE:  
133 <221> NAME/KEY: Oligonucleotide  
134 <400> SEQUENCE: 15  
135 ccagcagagt cacgagagag actacacgg 29  
136 <210> SEQ ID NO 16  
137 <211> LENGTH: 25  
138 <212> TYPE: DNA  
139 <213> ORGANISM: Artificial Sequence  
140 <220> FEATURE:  
141 <221> NAME/KEY: Oligonucleotide  
142 <400> SEQUENCE: 16  
143 cacgagagag actacacggt actgg 25  
144 <210> SEQ ID NO 17

PAGE: 4

# RAW SEQUENCE LISTING PATENT APPLICATION US/09/191,997

DATE: 11/27/1998  
TIME: 16:46:46

Input Set: I191997.RAW

```

145 <211> LENGTH: 526
146 <212> TYPE: DNA
147 <213> ORGANISM: Homo Sapiens
148 <220> FEATURE:
149 <221> NAME/KEY: misc_feature
150 <222> LOCATION: complement(261..376)
151 <223> OTHER INFORMATION: blastn
152 <220> FEATURE:
153 <221> NAME/KEY: misc_feature
154 <222> LOCATION: complement(380..486)
155 <223> OTHER INFORMATION: blastn
156 <220> FEATURE:
157 <221> NAME/KEY: misc_feature
158 <222> LOCATION: complement(110..145)
159 <223> OTHER INFORMATION: blastn
160 <220> FEATURE:
161 <221> NAME/KEY: misc_feature
162 <222> LOCATION: complement(196..229)
163 <223> OTHER INFORMATION: blastn
164 <220> FEATURE:
165 <221> NAME/KEY: sig_peptide
166 <222> LOCATION: 90..140
167 <223> OTHER INFORMATION: Von Heijne matrix
168 <400> SEQUENCE: 17
169 aatatrarac agctacaata ttccagggcc artcacttgc cattttctcat aacagcgtca 60
170 gagagaaaga actgactgar acgtttgag atg aag aaa gtt ctc ctc ctg atc 113
171                                     Met Lys Lys Val Leu Leu Leu Ile
172                                     -15                               -10
173 aca gcc atc ttg gca gtg gct gtw ggt ttc cca gtc tct caa gac cag 161
174 Thr Ala Ile Leu Ala Val Ala Val Gly Phe Pro Val Ser Gln Asp Gln
175                               -5                               1                               5
176 gaa cga gaa aaa aga agt atc agt gac agc gat gaa tta gct tca ggr 209
177 Glu Arg Glu Lys Arg Ser Ile Ser Asp Ser Asp Glu Leu Ala Ser Gly
178                               10                               15                               20
179 wtt ttt gtg ttc cct tac cca tat cca ttt cgc cca ctt cca cca att 257
180 Xaa Phe Val Phe Pro Tyr Pro Tyr Pro Phe Arg Pro Leu Pro Pro Ile
181                               25                               30
W--> 182 cca ttt cca aga ttt cca tgg ttt aga cgt aat ttt cct att cca ata 305
183 Pro Phe Pro Arg Phe Pro Trp Phe Arg Arg Xaa Phe Pro Ile Pro Ile
184                               40                               45                               50                               55
185 cct gaa tct gcc cct aca act ccc ctt cct agc gaa aag taaacaaraa 354
186 Pro Glu Ser Ala Pro Thr Thr Pro Leu Pro Ser Glu Lys
187                               60                               65
188 ggaaaagtca crataaacct ggtcacctga aattgaaatt gagccacttc cttgaaraat 414
189 caaaattcct gttaataaaa raaaaacaaa tgtaattgaa atagcacaca gcattctcta 474
190 gtcaatatct ttagtgatct tctttaataa acatgaaagc aaaaaaaaaa aa 526
191 <210> SEQ ID NO 18
192 <211> LENGTH: 17
193 <212> TYPE: PRT
194 <213> ORGANISM: Homo Sapiens

```

**Please Note:**

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

PATENT

Case Docket No. GENSET.016A


Date: August 3, 1999

(X) Fees as calculated below:

FEE FOR EXTENSION OF TIME (LARGE ENTITY)	4 months	\$ 1,360
SURCHARGE 37 CFR 1.16(e)		\$ + 130
TOTAL OF ABOVE CALCULATIONS		\$ 1,490
REDUCTION BY 1/2 FOR FILING BY SMALL ENTITY.		
Note 37 CFR 1.9, 1.27, 1.28. If applicable, verified statement must be attached.		\$ - 0
TOTAL FEES SUBMITTED HEREWITH		\$ 1,490

(X) A check in the amount of \$1,490 to cover the above fees is enclosed.

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410. A duplicate copy of this sheet is enclosed.



Daniel Hart

Registration No. 40,637

Attorney of Record



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Dumas Milne Edwards et al.	)	Group Art Unit 1646
			)	
Appl. No.	:	09/191,997	)	I hereby certify that this correspondence and all
			)	marked attachments are being deposited with
Filed	:	November 13, 1998	)	the United States Postal Service as first-class
			)	mail in an envelope addressed to: Assistant
For	:	EXTENDED CDNAS FOR	)	Commissioner for Patents, Washington, D.C.
		SECRETED PROTEINS	)	20231, on
			)	
Examiner	:	Unknown	)	

August 3, 1999  
(Date)  
*Daniel Hart*  
Daniel Hart, Reg. No. 40,637

LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

The Applicants respectfully request that the full last name of the first inventor be used in all communications from the Patent and Trademark Office. Kindly note that the last name of the first named inventor, (Jean-Baptiste Dumas Milne Edwards), is Dumas Milne Edwards.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: August 3, 1999

By: *Daniel Hart*  
Daniel Hart  
Registration No. 40,637  
Attorney of Record  
620 Newport Center Drive, 16<sup>th</sup> Floor  
Newport Beach, CA 92660  
(619) 235-8550